J. Listing

发表

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

H. Zeidler, W. Golder, A. Krause, 2002, The Lancet.

A Nonparametric Test for Random Dropouts

J. Listing, R. Schlittgen, 2003 .

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

M. Dougados, D. M. van der Heijde, R. Landewé, 2009, Annals of the rheumatic diseases.

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

E. Feist, H. Schulze-Koops, J. Listing, 2020, Annals of the Rheumatic Diseases.

Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.

J. Braun, J. Listing, A. Zink, 2000, The Journal of rheumatology.

Burden and cost of illness in patients with juvenile idiopathic arthritis

K. Minden, J. Listing, A. Zink, 2004, Annals of the rheumatic diseases.

Rheumatoid arthritis - treatment 180. Utility of Body Weight Classified Low-Dose Leflunomide in Japanese Rheumatoid Arthritis

Stanley B. Cohen, D. Symmons, M. Dougados, 2011 .

Robustness of subset selection procedures.

D. Rasch, J. Listing, 1996 .

Atopic disorders in ankylosing spondylitis and rheumatoid arthritis

J. Braun, J. Listing, A. Zink, 2002, Annals of the rheumatic diseases.

A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.

W. Dixon, F. Wolfe, J. Kremer, 2010, Seminars in arthritis and rheumatism.

Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the national database of the German Collaborative Arthritis Centres

R. Fischer-Betz, E. Gromnica-ihle, J. Listing, 2004, Lupus.

Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria.

J. Braun, J. Listing, J. Sieper, 2006, Arthritis and rheumatism.

Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort

J. Listing, A. Zink, B. Manger, 2017, Annals of the rheumatic diseases.

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

W. Dixon, D. Ray, M. D. de Wit, 2016, Annals of the rheumatic diseases.

[Dose adjustment in patients treated with infliximab in routine rheumatologic care in Germany. Results from the Biologics Register RABBIT].

E. Gromnica-ihle, J. Listing, A. Zink, 2006, Zeitschrift fur Rheumatologie.

Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care

J. Braun, J. Listing, J. Sieper, 2018, RMD Open.

Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Long‐Term Anti–Tumor Necrosis Factor Treatment: Six‐Year Results of Continuous Treatment With Etanercept

J. Listing, J. Sieper, K. Hermann, 2019, Arthritis & rheumatology.

Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis--3-Year data of the ESTHER trial.

J. Listing, J. Sieper, B. Freundlich, 2016, Seminars in arthritis and rheumatism.

Consistently Good Clinical Response in Patients with Early Axial Spondyloarthritis After 3 Years of Continuous Treatment with Etanercept: Longterm Data of the ESTHER Trial

J. Listing, J. Sieper, B. Freundlich, 2014, The Journal of Rheumatology.

Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial

J. Braun, J. Listing, J. Sieper, 2013, Annals of the rheumatic diseases.

Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers

J. Listing, J. Sieper, H. Haibel, 2014, Arthritis Research & Therapy.

J. Listing, J. Sieper, B. Freundlich, 2012, Annals of the rheumatic diseases.

Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48

J. Listing, J. Sieper, B. Freundlich, 2011, Annals of the rheumatic diseases.

The Natural Course of Radiographic Progression in Ankylosing Spondylitis: Differences Between Genders and Appearance of Characteristic Radiographic Features

J. Braun, J. Listing, X. Baraliakos, 2011, Current rheumatology reports.

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis

J. Braun, J. Listing, J. Sieper, 2008, Arthritis research & therapy.

Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes

J. Braun, J. Brandt, J. Listing, 2007, Annals of the rheumatic diseases.

Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging

D. M. van der Heijde, R. Landewé, J. Braun, 2004, Annals of the rheumatic diseases.

Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging ( MRI ) – a comparison between contrast enhanced T 1 and short-tau inversion recovery ( STIR ) sequences

D. M. van der Heijde, R. Landewé, D. V. D. Heijde, 2005 .

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis

J. Braun, J. Listing, J. Sieper, 2007, Annals of the rheumatic diseases.

Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial

U. Syrbe, J. Listing, J. Sieper, 2017, Arthritis Research & Therapy.

Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial

G. Burmester, J. Listing, J. Sieper, 2012, Annals of the rheumatic diseases.

The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis

H. Zeidler, J. Listing, A. Zink, 2001, Annals of the rheumatic diseases.

TESTS IF DROPOUTS ARE MISSED AT RANDOM

J. Listing, R. Schlittgen, 1998 .

Employment across chronic inflammatory rheumatic diseases and comparison with the general population.

H. Zeidler, J. Listing, A. Zink, 2005, The Journal of rheumatology.

The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database.

K. Minden, J. Listing, A. Zink, 2009, Clinical and experimental rheumatology.

Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy.

K. Minden, J. Meincke, J. Listing, 2000, The Journal of rheumatology.

Long-term outcome in patients with juvenile idiopathic arthritis.

K. Minden, J. Listing, A. Zink, 2002, Arthritis and rheumatism.

Incidence and prevalence of juvenile chronic arthritis in East Berlin 1980-88.

J. Meincke, J. Listing, A. Zink, 1998, The Journal of rheumatology.

Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment

J. Listing, J. Sieper, M. Rudwaleit, 2008, Arthritis research & therapy.

The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers.

W. Dixon, M. A. van de Laar, P. V. van Riel, 2015, Rheumatology.

Infections in patients with rheumatoid arthritis treated with biologic agents.

Matthias Schneider, Joachim Listing, Anja Strangfeld, 2005, Arthritis and rheumatism.

Risk of serious bacterial infection: treatment with anti-TNF versus methotrexate

J. Listing, A. Zink, 2007, Nature Clinical Practice Rheumatology.

The After 2 Years of Tumor Necrosis Factor Inhibitor Therapy Ankylosing Spondylitis Identified by Magnetic Resonance Imaging: Changes Vertebral Erosions Associated with Spinal Inflammation in Patients with

J. Braun, J. Listing, J. Sieper, 2013 .

Blood pressure- and lipid-lowering effect of mackerel and herring diet in patients with mild essential hypertension.

M. Wirth, C. Taube, J. Listing, 1985, Atherosclerosis.

Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.

Matthias Schneider, G. Burmester, H. Zeidler, 2007, The Journal of rheumatology.

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

M. Aringer, J. Listing, A. Zink, 2016, Annals of the rheumatic diseases.

Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.

D. M. van der Heijde, J. Braun, J. Listing, 2007, Arthritis and rheumatism.

Impact of anti-tumour necrosis factor α treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis

J. Braun, J. Brandt, J. Listing, 2004, Annals of the rheumatic diseases.

No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial

J. Listing, J. Sieper, H. Haibel, 2006, Annals of the rheumatic diseases.

Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort

A. Krause, J. Listing, A. Zink, 2017, Rheumatology International.

Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography

M. Dougados, D. M. van der Heijde, R. Landewé, 2013, Annals of the rheumatic diseases.

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.

J. Braun, J. Listing, J. Sieper, 2005, Arthritis and rheumatism.

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab

J. Braun, J. Braun, J. Brandt, 2005, Arthritis Research & Therapy.

Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers.

D. Symmons, M. Neovius, J. Askling, 2011, Rheumatology.

Practice variation in the treatment of rheumatoid arthritis among German rheumatologists.

S. Ziemer, H. Zeidler, J. Listing, 2001, The Journal of rheumatology.

ORAL TYPE I1 COLLAGEN TREATMENT IN EARLY RHEUMATOID ARTHRITIS

N. Mitchison, F. Hiepe, J. Braun, 1996 .

Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial.

N. Mitchison, F. Hiepe, J. Braun, 1996, Arthritis and rheumatism.

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti-TNF- Agents

J. Listing, A. Zink, P. Herzer, 2017 .

Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

J. Listing, A. Zink, P. Herzer, 2009, JAMA.

UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

David T Felson, Maxime Dougados, Peter Tugwell, 2011 .

Matthias Schneider, J. Listing, A. Zink, 2015, Rheumatology.

Treatment continuation in patients receiving biological agents or conventional DMARD therapy

R. Rau, S. Wassenberg, E. Gromnica-ihle, 2005, Annals of the rheumatic diseases.

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

J. Braun, J. Brandt, J. Listing, 2005, Arthritis research & therapy.

Sustainability of Rituximab Therapy in Different Treatment Strategies: Results of a 3-Year Followup of a German Biologics Register

J. Listing, A. Zink, A. Richter, 2014, Arthritis care & research.

Comparative effectiveness of tumour necrosis factor α inhibitors in combination with either methotrexate or leflunomide

J. Listing, A. Zink, H. Tony, 2009, Annals of the rheumatic diseases.

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register

G. Burmester, R. Rau, E. Gromnica-ihle, 2006, Arthritis research & therapy.

Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis.

S. Wassenberg, J. Listing, A. Zink, 2020, Seminars in arthritis and rheumatism.

Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept

J. Braun, J. Brandt, J. Listing, 2005, Annals of the rheumatic diseases.

The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort.

E. Märker-Hermann, H. Zeidler, J. Braun, 2009, Arthritis and rheumatism.

Relation of HLA-B27, Tumor Necrosis Factor-α Promoter Gene Polymorphisms, and T Cell Cytokine Production in Ankylosing Spondylitis — A Comprehensive Genotype-Phenotype Analysis from an Observational Cohort

E. Märker-Hermann, H. Zeidler, J. Braun, 2011, The Journal of Rheumatology.

Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.

Jürgen Braun, Joachim Listing, Joachim Sieper, 2006, Arthritis and rheumatism.

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.

J. Braun, J. Brandt, J. Listing, 2005, Arthritis and rheumatism.

Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.

J. Braun, J. Brandt, J. Listing, 2005, Rheumatology.

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

H. Zeidler, G. Burmester, G. Burmester, 2005, Rheumatology.

Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.

J. Braun, J. Brandt, J. Listing, 2005, Rheumatology.

Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis

H. Zeidler, G. Burmester, G. Burmester, 2004, Annals of the rheumatic diseases.

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis

J. Braun, J. Brandt, J. Listing, 2004, Annals of the rheumatic diseases.

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.

D. M. van der Heijde, W. Golder, J. Braun, 2003, Arthritis and rheumatism.

Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis

J. Listing, A. Zink, J. Sieper, 2014, Annals of the rheumatic diseases.

Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

J. Listing, J. Sieper, K. Hermann, 2014, Annals of the rheumatic diseases.

Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis

J. Braun, J. Listing, J. Sieper, 2013, Annals of the rheumatic diseases.

Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare.

J. Braun, J. Listing, J. Sieper, 2013, Arthritis and rheumatism.

Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.

Matthias Schneider, G. Burmester, A. Krause, 2011, Rheumatology.

Biologic therapies in the spondyloarthritis: new opportunities, new challenges

Jan Brandt, Joachim Listing, Joachim Sieper, 2003, Current opinion in rheumatology.

Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.

J. Braun, J. Listing, J. Sieper, 2010, Arthritis and rheumatism.

Extended Report

M. Eveslage, J. Listing, A. Zink, 2011 .

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT

G. Burmester, R. Rau, J. Listing, 2010, Arthritis research & therapy.

Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort

E. Märker-Hermann, H. Zeidler, J. Braun, 2012, Annals of the rheumatic diseases.

Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.

H. Zeidler, G. Burmester, W. Golder, 2003, Arthritis and rheumatism.

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

J. Braun, J. Brandt, J. Listing, 2003, Arthritis and rheumatism.

Bacterial and opportunistic infections during anti-TNF therapy

J. Listing, A. Strangfeld, 2006 .

Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.

J. Listing, A. Strangfeld, 2006, Best practice & research. Clinical rheumatology.

The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.

J. Listing, A. Zink, K. Gerhold, 2013, Rheumatology.

Open label trial of anakinra in active ankylosing spondylitis over 24 weeks

J. Listing, J. Sieper, H. Haibel, 2004, Annals of the rheumatic diseases.

THU0285 No evidence for a role of the hypothesized sequence inflammation - fatty degeneration – new bone formation in patients with ankylosing spondylitis treated with infliximab or other anti-TNF agents over 5 years

D. Pappas, J. Braun, J. Listing, 2013 .

Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

Matthias Schneider, S. Wassenberg, J. Listing, 2008, Arthritis and rheumatism.

Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems

D. M. van der Heijde, W. Golder, J. Braun, 2004, Annals of the rheumatic diseases.

Genomic stratification by expression of HLA-DRB4 alleles identifies differential innate and adaptive immune transcriptional patterns - A strategy to detect predictors of methotrexate response in early rheumatoid arthritis.

R. Winchester, G. Burmester, P. Martus, 2016, Clinical immunology.

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers

W. Dixon, X. Mariette, J. Gottenberg, 2016, Annals of the rheumatic diseases.

Evaluation of the RABBIT Risk Score for serious infections

A. Krause, J. Listing, A. Zink, 2013, Annals of the rheumatic diseases.

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab

G. Burmester, J. Listing, A. Zink, 2013, Annals of the rheumatic diseases.

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

P. Tugwell, M. Dougados, M. D. de Wit, 2011, Arthritis and rheumatism.

Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort

J. Listing, J. Sieper, S. Knüppel, 2018, Rheumatology.

Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort

J. Listing, J. Sieper, H. Haibel, 2017, Arthritis Research & Therapy.

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab

J. Braun, J. Brandt, J. Listing, 2005 .

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial

Andreas Krause, G. Burmester, A. Krause, 2011, Annals of the rheumatic diseases.

Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years

J. Braun, J. Listing, J. Sieper, 2016, The Journal of Rheumatology.

Vertebral Erosions Associated with Spinal Inflammation in Patients with Ankylosing Spondylitis Identified by Magnetic Resonance Imaging: Changes After 2 Years of Tumor Necrosis Factor Inhibitor Therapy

J. Braun, J. Listing, J. Sieper, 2013, The Journal of Rheumatology.

Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis

E. Märker-Hermann, H. Zeidler, J. Braun, 2011, Annals of the rheumatic diseases.

The Natural Course of Radiographic Progression in Ankylosing Spondylitis — Evidence for Major Individual Variations in a Large Proportion of Patients

J. Braun, J. Listing, X. Baraliakos, 2009, The Journal of Rheumatology.

Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis.

J. Zwerina, G. Schett, M. Herrmann, 2009, Arthritis and rheumatism.

Evaluation of 2 Screening Strategies for Early Identification of Patients with Axial Spondyloarthritis in Primary Care

J. Listing, J. Sieper, D. Poddubnyy, 2011, The Journal of Rheumatology.

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two.

J. Braun, J. Listing, J. Sieper, 2008, Arthritis and rheumatism.

A comparison of new bone formation in patients with ankylosing spondylitis and patients with diffuse idiopathic skeletal hyperostosis: a retrospective cohort study over six years.

J. Buschmann, J. Braun, J. Listing, 2012, Arthritis and rheumatism.

ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis

D. M. van der Heijde, R. Landewé, D. Heijde, 2008, Annals of the rheumatic diseases.

Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)

U. Syrbe, J. Braun, J. Listing, 2015, Annals of the rheumatic diseases.

Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab.

J. Braun, J. Brandt, J. Listing, 2007, Rheumatology.

Development and preselection of criteria for short term improvement after anti-TNFα treatment in ankylosing spondylitis

D. Heijde, J. Braun, J. Brandt, 2004, Annals of the rheumatic diseases.

Course of active inflammatory and fatty lesions in patients with early axial spondyloarthritis treated with infliximab plus naproxen as compared to naproxen alone: Results from the INFAST study

J. Listing, J. Sieper, D. Poddubnyy, 2016 .

Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change.

J. Braun, J. Listing, J. Sieper, 2009, Arthritis and rheumatism.

Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations

J. Listing, J. Sieper, M. Rudwaleit, 2008, Annals of the rheumatic diseases.

Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice.

J. Listing, J. Sieper, H. Haibel, 2008, Clinical and experimental rheumatology.

Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis.

E. Märker-Hermann, H. Zeidler, J. Braun, 2012, Arthritis and rheumatism.

High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis

J. Zwerina, G. Schett, J. Listing, 2011, Annals of the rheumatic diseases.

Extended report

J. Listing, J. Sieper, B. Freundlich, 2011 .

HLA-DRB1 genes, rheumatoid factor, and elevated C-reactive protein: independent risk factors of radiographic progression in early rheumatoid arthritis. Berlin Collaborating Rheumatological Study Group.

R. Rau, D. Hagemann, E. Gromnica-ihle, 2000, The Journal of rheumatology.

Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response

Andreas Krause, H. Zeidler, G. Burmester, 2007, Annals of the rheumatic diseases.

FRI0397 The Diagnostic Value of The Symptom of Inflammatory Back Pain in Axial Spondyloarthritis in The Rheumatology Setting

J. Braun, J. Listing, J. Sieper, 2016 .

The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab.

M. Dougados, P. Geusens, R. Landewé, 2011, Clinical and experimental rheumatology.

The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients

H. Zeidler, J. Listing, A. Zink, 2001, Annals of the rheumatic diseases.

Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis.

Matthias Schneider, S. Wassenberg, E. Gromnica-ihle, 2006, The Journal of rheumatology.

The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers: results of the German multicenter inception cohort (ICON)

A. Heiligenhaus, D. Foell, K. Minden, 2018, Arthritis Research & Therapy.

Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis

J. Listing, A. Zink, M. Schneider, 2015, Annals of the rheumatic diseases.

Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.

Matthias Schneider, S. Wassenberg, J. Listing, 2006, Arthritis and rheumatism.

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

G. Burmester, F. Buttgereit, R. Rau, 2012, Annals of the rheumatic diseases.

Loss of physical independence in rheumatoid arthritis: interview data from a representative sample of patients in rheumatologic care.

J. Listing, A. Zink, G. Westhoff, 2000, Arthritis care and research : the official journal of the Arthritis Health Professions Association.

Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis

J. Listing, A. Zink, S. Berger, 2019, Rheumatology.

OP0017 Pregnancies in Patients with Rheumatoid Arthritis: Treatment Decisions, Course of the Disease, and Pregnancy Outcomes

J. Listing, A. Zink, B. Krummel-Lorenz, 2015 .

One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare

J. Braun, J. Listing, J. Sieper, 2012, Annals of the rheumatic diseases.

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal

M. Dougados, B. Dijkmans, I. Olivieri, 2009, Annals of the rheumatic diseases.

Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial.

J. Listing, J. Sieper, B. Freundlich, 2015, Rheumatology.

Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC)

E. Märker-Hermann, H. Zeidler, J. Braun, 2013, Annals of the rheumatic diseases.

Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project

W. Dixon, F. Tubach, X. Mariette, 2017, Annals of the rheumatic diseases.

Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis

J. Listing, A. Zink, A. Richter, 2016, Arthritis Research & Therapy.

Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still’s Disease and Active Articular Manifestation Responding to Canakinumab

D. Foell, E. Feist, G. Burmester, 2021, Journal of clinical medicine.

THU0272 Efficacy of oral prednisolone in active ankylosing spondylitis – results of a double blind placebo controlled trial

J. Braun, J. Listing, J. Sieper, 2013 .

EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology

W. Dixon, R. Landewé, L. Carmona, 2010, Annals of the rheumatic diseases.

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years

J. Braun, J. Listing, J. Sieper, 2013, Arthritis Research & Therapy.

Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.

J. Braun, J. Brandt, J. Listing, 2004, The Journal of rheumatology.

THU0142 The prognosis of heart failure in patients with rheumatoid arthritis

J. Listing, B. Manger, A. Strangfeld, 2018, THURSDAY, 14 JUNE 2018.

Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years

J. Braun, J. Brandt, J. Listing, 2005, Arthritis Research & Therapy.

Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial

G. Burmester, F. Buttgereit, R. Rau, 2014, Trials.

O07. First Results of a European Registries Collaborative Project to Describe the Spectrum of Lymphomas Across Different Drug Treatment Groups in Rheumatoid Arthritis

W. Dixon, F. Tubach, X. Mariette, 2015 .

Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis

J. Braun, J. Listing, J. Sieper, 2010, Annals of the rheumatic diseases.

opinion including uncertainty appraisal (part I): classification of paper patients by expert classification criteria for axial spondyloarthritis SpondyloArthritis international Society The development of Assessment of

M. Dougados, B. Dijkmans, I. Olivieri, 2009 .

Health care provision in pediatric rheumatology in Germany--national rheumatologic database.

K. Minden, J. Listing, A. Zink, 2002, The Journal of rheumatology.

Ankylosing spondylitis self-help organisations - do members differ from non-members?

J. Listing, J. Sieper, M. Rudwaleit, 2016, Joint, bone, spine : revue du rhumatisme.

Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study—a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

F. Buttgereit, R. Rau, S. Wassenberg, 2021, RMD Open.

Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.

J. Listing, A. Zink, J. Callhoff, 2013, Rheumatology.

Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC

K. Minden, J. Listing, J. Sieper, 2017, RMD Open.

Differential expression of HLA class II genes associated with disease susceptibility and progression in rheumatoid arthritis.

Christian Heldt, Joachim Listing, S. Frischbutter, 2003, Arthritis and rheumatism.

[Biomarkers in rheumatology. Biomarkers and imaging for the diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the ArthroMark network funded by the Federal Ministry of Education and Research].

G. Burmester, B. Hoppe, T. Häupl, 2012, Zeitschrift fur Rheumatologie.

[Out-of-pocket medical spending for care in patients with recent onset rheumatoid arthritis].

J. Listing, A. Zink, G. Westhoff, 2004, Zeitschrift fur Rheumatologie.

THU0262 Sclerostin does not predict radiographic progression in patients on anti-tnf therapy – new results from the european ankylosing spondylitis (AS) infliximab cohort (EASIC)

M. Dougados, R. Landewé, P. Emery, 2013 .

Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF- a antibody infliximab

J. Braun, J. Brandt, J. Listing, 2022 .

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

J. Braun, J. Brandt, J. Listing, 2005 .

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis

J. Braun, J. Listing, J. Sieper, 2008, Arthritis research & therapy.

Response to: ‘Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still’s disease’ by Ruscitti et al

E. Feist, J. Listing, C. Kedor, 2020, Annals of the Rheumatic Diseases.

OP0018 COMPARISON OF THE EFFECT OF TREATMENT WITH NSAIDs ADDED TO ANTI-TNF THERAPY VERSUS ANTI-TNF THERAPY ALONE ON PROGRESSION OF STRUCTURAL DAMAGE IN THE SPINE OVER TWO YEARS IN PATIENTS WITH ANKYLOSING SPONDYLITIS (CONSUL) – AN OPEN-LABEL, RANDOMIZED CONTROLLED, MULTICENTER TRIAL

B. Muche, J. Listing, U. Kiltz, 2022, Annals of the Rheumatic Diseases.

FRI0294 Biologic Monotherapy: A Treatment Option for Elderly RA Patients with Multimorbid Conditions

J. Listing, A. Zink, A. Richter, 2014 .

[Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany].

J. Braun, J. Brandt, J. Listing, 2003, Zeitschrift fur Rheumatologie.

OP0155 Ustekinumab Effectively Reduces Active Inflammation as Detected by Magnetic Resonance Imaging in Patients with Active Ankylosing Spondylitis: Results of A 28-Week, Prospective, Open-Label, Proof-Of-Concept Study (TOPAS)

J. Listing, J. Sieper, K. Hermann, 2014 .

Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level

J. Listing, D. M., Emery P Efficacy, 2006 .

Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

J. Listing, A. Zink, P. Herzer, 2009, JAMA.

Implementing an automated monitoring process in a digital, longitudinal observational cohort study

Georg Schett, Lisa Lindner, Anja Weiß, 2021, Arthritis Research & Therapy.

Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis.

E. Märker-Hermann, H. Zeidler, J. Braun, 2012, Arthritis and rheumatism.

Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

J. Listing, J. Sieper, K. Hermann, 2014, Annals of the rheumatic diseases.

THU0561 CANAKINUMAB FOR THE TREATMENT OF ADULT ONSET STILL‘S DISEASE TO ACHIEVE REDUCTION OF ARTHRITIC MANIFESTATION AT WEEK 12: AN INVESTIGATOR-INITIATED MULTI-CENTRE, PLACEBO-CONTROLLED STUDY (CONSIDER)

E. Feist, H. Schulze-Koops, J. Listing, 2019, Poster Presentations.

Canakinumab for Treatment of Adult Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): A Phase 2, Multi-Centre, Placebo-Controlled Study

E. Feist, H. Schulze-Koops, J. Listing, 2019, SSRN Electronic Journal.